Vaccine for Grass Pollen Allergy and House Dust Mite Allergy is under clinical development by Allergy Therapeutics and currently in Phase II for House Dust Mite Allergy. According to GlobalData, Phase II drugs for House Dust Mite Allergy have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vaccine for Grass Pollen Allergy and House Dust Mite Allergy’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vaccine for Grass Pollen Allergy and House Dust Mite Allergy overview
Vaccine candidate is under development for the treatment or prevention of grass pollen allergy, trees & house dust mite allergy. It is administered through sublingual route. The vaccine candidate is developed based on OralVac technology platform which uses sublingual immunotherapy SLIT treatments that aim to desensitize severe allergy patients to various common allergens.
See Also:
Allergy Therapeutics overview
Allergy Therapeutics is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminum-free allergy vaccines and diagnostics. Allergy Therapeutics product portfolio includes Grass Modified Allergen Tyrosine Adsorbed (MATA), Tree MATA, Ragweed MATA, Bee Venom Subcutaneous Immunotherapy (SCIT), and Wasp venom SCIT among others. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise of Pollen, Moulds, Arthropods, Epithelia and others. It has operational presence in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the UK among others. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.
For a complete picture of Vaccine for Grass Pollen Allergy and House Dust Mite Allergy’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
